{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:09:32Z","timestamp":1790222972776,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/mao.0b013e3181a52773","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T16:23:21Z","timestamp":1242923001000},"page":"443-448","source":"Crossref","is-referenced-by-count":69,"title":["Safety of High-Dose Corticosteroids for the Treatment of Autoimmune Inner Ear Disease"],"prefix":"10.1097","volume":"30","author":[{"given":"Thomas H.","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Derebery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Espeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Gantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Julianna","family":"Gulya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Hammerschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Hannley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moscicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Niparko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Telian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Brookhouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210212","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/000348947908800501","article-title":"Autoimmune sensorineural hearing loss.","volume":"88","author":"McCabe","year":"1979","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R2-3-20210212","first-page":"196","article-title":"Autoimmune inner ear disease: therapy.","volume":"10","author":"McCabe","year":"1989","journal-title":"Am J Otol"},{"key":"R3-3-20210212","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1529-0131(200104)45:2<146::AID-ANR167>3.0.CO;2-I","article-title":"Open trial of methotrexate as treatment for autoimmune hearing loss.","volume":"45","author":"Matteson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R4-3-20210212","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0194-5998(97)70316-4","article-title":"Methotrexate management of immune-mediated cochleovestibular disorders.","volume":"116","author":"Sismanis","year":"1997","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R5-3-20210212","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.290.14.1875","article-title":"Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.","volume":"290","author":"Harris","year":"2003","journal-title":"JAMA"},{"key":"R6-3-20210212","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.mao.0000185082.28598.87","article-title":"Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.","volume":"26","author":"Cohen","year":"2005","journal-title":"Otol Neurotol"},{"key":"R7-3-20210212","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000095897","article-title":"Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.","volume":"11","author":"Van Wijk","year":"2006","journal-title":"Audiol Neurootol"},{"key":"R8-3-20210212","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/030006059302100404","article-title":"Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease.","volume":"21","author":"Saracaydin","year":"1993","journal-title":"J Int Med Res"},{"key":"R9-3-20210212","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.semarthrit.2004.07.001","article-title":"Immune-mediated inner ear disease: 10-year experience.","volume":"34","author":"Broughton","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R10-3-20210212","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1288\/00005537-198911000-00006","article-title":"Theoretical and practical implications for plasmapheresis in autoimmune inner ear disease.","volume":"99","author":"Luetje","year":"1989","journal-title":"Laryngoscope"},{"key":"R11-3-20210212","first-page":"572","article-title":"Plasmapheresis in autoimmune inner ear disease: long-term follow-up.","volume":"18","author":"Luetje","year":"1997","journal-title":"Am J Otol"},{"key":"R12-3-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0194-5998(95)70170-2","article-title":"Fundamental immune mechanisms of the brain and inner ear.","volume":"112","author":"Harris","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R13-3-20210212","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.0307-7772.2003.00738.x","article-title":"Autoimmune sensorineural hearing loss.","volume":"28","author":"Mathews","year":"2003","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"R14-3-20210212","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.moo.0000136101.95662.aa","article-title":"Autoimmune inner ear disease.","volume":"12","author":"Ruckenstein","year":"2004","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"R16-3-20210212","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events.","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R18-3-20210212","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.mao.0000185081.28598.5c","article-title":"Serial audiometry in a clinical trial of AIED treatment.","volume":"26","author":"Niparko","year":"2005","journal-title":"Otol Neurotol"},{"key":"R19-3-20210212","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.semarthrit.2003.10.002","article-title":"Autoimmune sensorineural hearing loss: clinical course and treatment outcome.","volume":"34","author":"Loveman","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R21-3-20210212","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archotol.131.8.665","article-title":"Corticosteroid response and supporting cell antibody in autoimmune hearing loss.","volume":"131","author":"Zeitoun","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R22-3-20210212","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":"Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy.","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet"},{"key":"R23-3-20210212","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"R24-3-20210212","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"R25-3-20210212","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use.","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R26-3-20210212","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00002018-200023040-00002","article-title":"Drug-induced rheumatic disorders: incidence, prevention and management.","volume":"23","author":"Vergne","year":"2000","journal-title":"Drug Saf"},{"key":"R27-3-20210212","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/bmj.293.6560.1463","article-title":"Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica.","volume":"293","author":"Reid","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R28-3-20210212","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0091-6749(98)70351-3","article-title":"Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months.","volume":"101","author":"Wang","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"R29-3-20210212","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R30-3-20210212","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"R31-3-20210212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"R32-3-20210212","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","article-title":"Pathogenesis and natural history of osteonecrosis.","volume":"32","author":"Assouline-Dayan","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"R33-3-20210212","first-page":"242","article-title":"Ischemic necrosis of femoral head. Part I. Accumulative cell stress: a hypothesis for the etiology of idiopathic osteonecrosis.","volume":"32","author":"Kenzora","year":"1983","journal-title":"Instr Course Lect"},{"key":"R34-3-20210212","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3928\/0147-7447-19961101-07","article-title":"Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy.","volume":"19","author":"Colwell","year":"1996","journal-title":"Orthopedics"},{"key":"R35-3-20210212","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2337\/diacare.6.5.488","article-title":"Urinary C-peptide as a measure of beta-cell function after a mixed meal in healthy subjects: comparison of four-hour urine C-peptide with serum insulin and plasma C-peptide.","volume":"6","author":"Hoogwerf","year":"1983","journal-title":"Diabetes Care"},{"key":"R36-3-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/dmr.5610040105","article-title":"Effects of glucocorticoids on carbohydrate metabolism.","volume":"4","author":"McMahon","year":"1988","journal-title":"Diabetes Metab Rev"},{"key":"R37-3-20210212","first-page":"2621","article-title":"High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men.","volume":"81","author":"Matsumoto","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-3-20210212","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0889-857X(05)70083-1","article-title":"Drug selection and the management of corticosteroid-related diabetes mellitus.","volume":"25","author":"Hoogwerf","year":"1999","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Otology &amp; Neurotology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MAO.0b013e3181a52773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:50:58Z","timestamp":1786038658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00129492-200906000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mao.0b013e3181a52773","relation":{},"ISSN":["1531-7129"],"issn-type":[{"value":"1531-7129","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}